The Preventive and Treatment of the Neuro-Inflammasome in Sorokdo National Hospital

Abstract

Aim/Background: This study investigated patients with Alzheimer's disease (AD) treated with 4,4’-diaminodiphenyl sulfone (DDS) as a neuro-inflammasome competitor. Method: The Seoul study analyzed AD, and anti-AD drugs (AADs) in the Sorokdo National Hospital's EDI database archived from January 2005 to June 2020 through the ICD-9 and -10 codes. Result: DDS acts as a neuro-inflammasome competitor; this effect can be inferred by comparing the prevalence of AD in patients who have been prescribed DDS and those who have not. Conclusion: This study suggests the use of neuro-inflammasome therapy as a preventive and therapeutic method for AD.

Commentary The Elderly in the pandemic era

“…Furthermore, he created the Seoul cohort under the assumption that it would expand cerebrovascular blood vessels with anticipation for the action of the sulfone group of Dapsone. In December 2020, the study confirmed that the action of Dapsone was on the neuro-inflammasome [9] [10].…”

“…It was always newly developed drugs that treat significant diseases, but Dapsone was used to improve treatment efficiency. However, to date, dapsone has been the treatment and preventive drug for mild cognitive impairment [8] [19], Alzheimer's disease [10], Parkinson's disease [20] [21], Seizure [22], Stroke [9] [23] [24] and Covid-19 ARDS [25] [13].…”

Dementia Management Act and Death Toll by Dementia Drug

“…When a patient taking dapsone, mainly used in clinical studies on in ammasome competitors 56 19 70 , stopped it for stroke treatment and administered acetylcholine precursors for dementia care, the patient's courses were rapidly progressed to severe hypertension and neurologic abnormalities 55 .…”

Death Toll by Dementia Drug

“…If AAD itself was not staged as a biomarker (D), the patient was bound to a bed, and making the patient's condition worse 54 . When connected with the Sorokdo National Hospital's EDI database, we could evaluate AAD prescriptions for fteen years 55 . Three ChEIs are approved for use in mild to moderate AD, and their symptomatic bene t in AD has been con rmed via meta-analyses assessing both cognitive performance and global functioning 56 .…”

“…When a patient taking dapsone, mainly used in clinical studies on in ammasome competitors 19,55,72 , stopped it for stroke treatment and administered acetylcholine precursors for dementia care, the patient's courses were rapidly progressed to severe hypertension and neurologic abnormalities 54 .…”